Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalActa medica Okayama
Volume73
Issue number2
Publication statusPublished - 2019
Externally publishedYes

Keywords

  • Cytarabine
  • Down syndrome
  • Exchange transfusion
  • Hydrops fetalis
  • Transient abnormal myelopoiesis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis'. Together they form a unique fingerprint.

  • Cite this